PMID: 9174194Jun 1, 1997Paper

In vitro and in vivo activities of AM-1155, a new fluoroquinolone, against Chlamydia spp

Antimicrobial Agents and Chemotherapy
N MiyashitaT Matsushima

Abstract

The in vitro and in vivo activities of AM-1155, a new quinolone, against Chlamydia spp. were investigated. The MIC of AM-1155 for 10 standard strains of different Chlamydia spp. and 25 wild-type strains of Chlamydia pneumoniae isolated in Japan, which were morphologically different from clinical isolates from the United States, ranged from 0.063 to 0.125 microg/ml. Its activity was almost the same as those of sparfloxacin and tosufloxacin and was 4 and 16 times superior to those of levofloxacin and ciprofloxacin, respectively, but lower than those of clarithromycin and minocycline (range for each, 0.016 to 0.031 microg/ml). The minimal chlamydiacidal concentration of AM-1155 ranged from 0.063 to 0.125 microg/ml, while those of clarithromycin and minocycline ranged from 0.016 to 0.031 microg/ml and 0.016 to 0.063 microg/ml, respectively. The therapeutic effect of a 7-day course of AM-1155 at doses of 5 and 10 mg/kg of body weight administered orally twice daily to mice with experimental Chlamydia psittaci pneumonia was excellent, with a 100% survival rate at 21 days after infection. The efficacy was equal to those of clarithromycin and minocycline and higher than those of ciprofloxacin and ofloxacin.

References

Mar 1, 1992·Antimicrobial Agents and Chemotherapy·M R HammerschlagP M Roblin
Jul 1, 1992·Antimicrobial Agents and Chemotherapy·M R HammerschlagP M Roblin
Oct 1, 1992·Antimicrobial Agents and Chemotherapy·M HosakaK Hirai
Apr 1, 1990·The Journal of Infectious Diseases·J T GraystonS P Wang
Mar 1, 1989·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·J T GraystonL A Campbell
Feb 1, 1988·Antimicrobial Agents and Chemotherapy·C C Kuo, J T Grayston
Jul 17, 1986·The New England Journal of Medicine·J T GraystonJ Altman
Dec 1, 1994·The Journal of Antimicrobial Chemotherapy·K IshidaN Suyama
Jan 1, 1994·Microbiology and Immunology·N MiyashitaA Matsumoto
Jul 1, 1994·Archives of Pediatrics & Adolescent Medicine·U EmreJ Schachter
Mar 1, 1994·Antimicrobial Agents and Chemotherapy·E Wakabayashi, S Mitsuhashi
Jun 1, 1993·Journal of Medical Microbiology·N MiyashitaA Matsumoto
Aug 1, 1995·The Journal of Antimicrobial Chemotherapy·M HosakaT Nishino
Dec 1, 1995·Antimicrobial Agents and Chemotherapy·M NakashimaH Uchida

❮ Previous
Next ❯

Citations

Jul 15, 1999·The Journal of Antimicrobial Chemotherapy·M DonatiR Cevenini
Dec 10, 1999·The Journal of Antimicrobial Chemotherapy·P M Roblin, M R Hammerschlag
Feb 24, 2001·Pharmacotherapy·D N Fish, D S North
Mar 7, 2003·Journal of Medical Microbiology·Naoyuki MiyashitaToshiharu Matsushima
Jul 2, 2003·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·Masaki Hosaka
Oct 13, 2006·Current Opinion in Infectious Diseases·L A Mandell
Sep 15, 2005·Internal Medicine·Naoyuki MiyashitaMikio Oka
Oct 16, 2001·Antimicrobial Agents and Chemotherapy·N MiyashitaT Matsushima
Aug 17, 2002·Antimicrobial Agents and Chemotherapy·M MaurinD Raoult
Jul 5, 2005·Expert Opinion on Investigational Drugs·P BallG Tillotson
Jun 25, 2003·Antimicrobial Agents and Chemotherapy·Satoshi AmeyamaMasahiro Takahata
Dec 13, 2006·Treatments in Respiratory Medicine·George G ZhanelDaryl J Hoban
May 23, 2003·Antimicrobial Agents and Chemotherapy·Hiroyuki YamaguchiYoshimasa Yamamoto
Jun 1, 2000·Microbiology and Immunology·N MiyashitaT Matsushima
Nov 4, 2000·Expert Opinion on Investigational Drugs·J M Blondeau
Apr 1, 2009·Antimicrobial Agents and Chemotherapy·Geneviève Goy, Gilbert Greub
May 26, 2010·Journal of Avian Medicine and Surgery·David Sanchez-Migallon GuzmanBranson Ritchie
Jan 23, 1999·Clinical Therapeutics·S M WimerM W Garrison
Nov 18, 2003·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·L DubreuilL Calvet
Jun 12, 2004·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·H LodeUNKNOWN International Gatifloxacin Study Group
Mar 12, 2005·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·F Van BambekeP M Tulkens

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Related Papers

Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy
N MiyashitaToshiharu Matsushima
Antimicrobial Agents and Chemotherapy
N MiyashitaT Matsushima
© 2021 Meta ULC. All rights reserved